Health

Seasonal Respiratory Tract Infections Prevention & Risk stratification

Winter poses a recurrent challenge for healthcare systems worldwide because of seasonal surges in respiratory tract infections (RTIs). These infections disproportionately affect “vulnerable” subpopulations — namely the elderly, infants and children, pregnant women, immunocompromised persons, and those with chronic comorbidities.

In intensive care practice — including in a cosmopolitan city such as Dubai with a diverse population — the burden of severe RTIs becomes evident each winter. Pneumonia, acute respiratory distress syndrome, exacerbation of chronic diseases, and multi-organ complications frequently present in high-risk patients admitted to ICUs. Preventive strategies, both at individual and public health level, are therefore of paramount importance.

This article synthesizes recent updates in medical literature (2024–2025) on prevention of RTIs, explores practical challenges from ICU experience, and advocates for strengthened measures to protect high-risk groups, especially during winter.

Why high-risk groups deserve special attention

A 2025 cross-disciplinary position paper from the United Arab Emirates specifically highlights that respiratory infections remain a major cause of mortality among young children and adults — particularly the elderly or those with underlying conditions — despite available vaccines and antiviral treatments.

According to guidelines from global health authorities, high-risk subpopulations are defined to include: children (especially infants), older adults, pregnant or postpartum women, immunocompromised individuals, and those with chronic diseases (e.g., cardiopulmonary, metabolic, renal).

For pregnant women, the stakes are even higher: a recent systematic review of human cases of avian influenza (A[H5]) during pregnancy reported maternal mortality as high as 90 %, and perinatal mortality (stillbirth/neonatal death) ~86.7 % among reported cases — underlining the extreme vulnerability of this population in the face of novel or zoonotic influenza viruses.

Moreover, infants and young children (<5 years) remain highly susceptible to viral lower RTIs: for example, Respiratory Syncytial Virus (RSV) induces a considerable global burden, with millions of hospitalizations and a high death toll in low- and middle-income countries.

Therefore, preventive measures must be prioritized — especially among these high-risk groups — to reduce both direct morbidity/mortality and downstream burdens on intensive care resources

High-Risk Groups for Severe Respiratory Tract Infections

Group	Reasons for Increased Risk	Clinical Impact
Pregnant women	Immunological shifts, reduced lung capacity	Severe pneumonia, preterm birth, fetal compromise
Infants & young children	Immature immune system	RSV bronchiolitis, viral pneumonia
Elderly	Immunosenescence, comorbidities	High hospitalization & mortality rates
Immunocompromised	Reduced viral clearance	Prolonged infections, severe disease
Chronic disease patients	Reduced physiological reserve	Exacerbations of COPD, asthma, CHF

Preventive strategies: vaccines and non-pharmaceutical interventions

Vaccination: cornerstone of prevention

Recent literature underscores the critical role of vaccination against major respiratory viruses. A narrative review published December 2024 demonstrated that immunization against SARS-CoV-2, influenza, and RSV significantly reduces severe disease, hospitalizations, and mortality among vulnerable individuals — including older adults and those with frailty or comorbidities.

For pregnant women, the guidance recently updated by the American College of Obstetricians and Gynecologists (ACOG) emphasizes that COVID-19 vaccination (including booster doses) is safe during pregnancy, and beneficial both for the mother and the newborn. Vaccination reduces maternal complications, preterm birth, stillbirth, and provides passive immunity to infants during early life.

Moreover, maternal immunization has demonstrated effectiveness in reducing neonatal and infant morbidity and mortality from respiratory viral infections. A 2025 review from India found that maternal immunization (e.g., influenza) substantially lowered deaths and severe outcomes in newborns — a critical consideration for countries with diverse perinatal populations.

In addition to influenza and COVID-19 vaccines, emerging preventive options for RSV are gaining traction; current evidence supports passive immunization in early infancy (e.g., monoclonal antibodies), and active immunization strategies are under development.

Finally, there may be indirect benefits from vaccines targeting bacterial pathogens: a systematic review showed that pneumococcal conjugate vaccines (PCVs) may reduce the incidence of viral RTIs by disrupting viral-bacterial interactions in the respiratory tract.

Given this, comprehensive immunization strategies — integrating influenza, COVID-19, RSV (as vaccines/antibodies become available), and pneumococcus — should form a central pillar of prevention, especially for high-risk individuals.

Non-pharmaceutical interventions and healthcare practices

Vaccination alone is not sufficient. According to guidance from the World Health Organization (WHO) Europe region, standard measures remain vital: staying home when ill, rigorous hand hygiene, cough etiquette, ensuring adequate indoor ventilation, and, in high-risk settings or crowded indoor spaces, mask-wearing and physical distancing when appropriate.

In healthcare settings — especially ICUs or wards managing severe RTIs — timely identification and triage, isolation or cohorting of suspected cases, use of droplet/contact (and when indicated, airborne) precautions during aerosol-generating procedures, and rapid initiation of antivirals (e.g., for influenza) are essential.

Also, the 2025 UAE position paper called for improved communication between healthcare professionals and patients to close gaps in vaccine uptake and adherence to prevention guidelines.

Call for reinforced preventive strategy in Dubai and similar contexts

Based on the convergence of recent evidence and practical ICU experience, I propose the following prioritized actions:

Promote vaccination aggressively, especially for high-risk groups (elderly, pregnant women, children, chronic disease, immunosuppressed) — including seasonal influenza and COVID-19 vaccines; and, as they become available or recommended, RSV and pneumococcal vaccines/antibodies.
Public health education: Raise awareness among patients and communities about the risks of RTIs, benefits of vaccination, and importance of early presentation in case of symptoms.
Hospital and community infection control: Reinforce NPIs — hand hygiene, cough etiquette, staying home if symptomatic, mask use in crowded indoor spaces or high-transmission periods; improve ventilation in households, workplaces, and public spaces.
Health-system readiness: Hospitals and ICUs should prepare protocols for timely triage, isolation/cohorting, and early antiviral therapy; public health authorities should monitor viral circulation and communicate risks effectively.
Perinatal care integration: Obstetricians, midwives, primary care providers should integrate respiratory virus vaccination (influenza, COVID-19) into routine antenatal and postnatal care, to protect both mothers and newborns.

Key Preventive Measures for Winter RTI Prevention

Level	Measure	Evidence & Impact
Individual	Annual influenza vaccine	Reduces severe disease & ICU admissions
	COVID-19 vaccine/booster	Reduces hospitalization & maternal-fetal risks
	Maternal vaccines (influenza, COVID-19, RSV)	Protects mothers + newborns
Household	Staying home when ill	WHO recommends as first-line prevention
	Good ventilation & hygiene	Reduces viral concentration indoors
	Masking when symptomatic	Particularly important for protecting infants
Healthcare system	Early testing & antiviral use	Reduces complications if started early
	Isolation/cohorting	Limits nosocomial transmission
	Public health communication	Enhances vaccine uptake (UAE 2025 position paper)
Community	Surveillance & seasonal alerts	Supports early preparedness

Why winter prevention matters — broader implications

Failure to implement preventive measures results not only in increased morbidity and mortality among vulnerable individuals, but also in broader health system strain. When ICUs are saturated with severe pneumonia cases, other critical care needs (e.g., trauma, surgery, non-respiratory emergencies) may be compromised.

Moreover, viral RTIs in high-risk populations — especially infants and the elderly — can lead to long-term sequelae (e.g., chronic lung disease, developmental issues in children, exacerbation of comorbidities in older adults). Preventive measures, therefore, contribute to healthier ageing and reduced long-term healthcare burden.

Finally, prevention — especially through vaccination — has societal and economic value: reduced hospitalizations, fewer workdays lost, lower risk of outbreaks in communities, and preservation of healthcare resources.

Conclusion

Seasonal surges in respiratory tract infections during winter remain a formidable challenge — particularly for high-risk groups such as pregnant women, children, and the elderly. Recent evidence (2024–2025) reaffirms that vaccination (influenza, COVID-19, and eventually RSV) combined with non-pharmaceutical measures are the most effective way to protect these vulnerable populations.

A coordinated approach — integrating public health outreach, perinatal care, community education, and healthcare system preparedness — is essential.

In the coming seasons, given the ever-present threat of viral evolution (including influenza and zoonotic viruses), robust prevention strategies are not optional — they are lifesaving.

Dr. Mahmoud Medhat Aboumousa

Critical Care Specialist

International Modern Hospital Dubai

Health

Novartis: Rare muscle disease drug shows early promise

Novartis (NOVN.S), opens new tab said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of ‌Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.

The Swiss ⁠drugmaker said the drug, known as del-brax, lowered two blood markers linked to the disease and showed reduced signs of muscle damage in patients with facioscapulohumeral muscular dystrophy.
Novartis said the drug shows potential to become the first disease-modifying ‌treatment ⁠for FSHD, which can cause weakness in the face, shoulders, arms and other muscles.
The company estimates it affects about 45,000 to ⁠87,000 people in the U.S. and EU.
The drug’s safety profile was consistent with previous ⁠results, the company said.
Novartis plans to discuss the data with health regulators ⁠around the world, while a late-stage study of the drug is currently enrolling patients.

The Thomson Reuters

Health

Obesity drug shows promise in reducing belly and liver fat

Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in ‌a late-stage study, data showed, bolstering its case for benefits beyond weight loss as competition in obesity drugs intensifies.

The drug, survodutide, was licensed from Denmark’s Zealand Pharma (ZELA.CO), opens new tab. An injectable that mimics the proteins GLP-1 and glucagon to create a feeling of fullness, its weight-loss trial results were announced in April, showing patients lost an average of 16.6% over 76 weeks.

Analysis of a group of patients who had MRI measurements at the start and end of a 76-week trial showed that survodutide reduced harmful ⁠abdominal fat by up to 34% and liver fat by up to 63.1% from the baseline, Boehringer said.

Analysts have said the weight-loss numbers were broadly comparable to existing GLP-1 injections from Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab and below newer rivals in development, and that the company needed to differentiate the drug’s benefits.

Lean mass accounted for no more than 10.8% of the change in body composition at the highest dose of 6 milligrams, suggesting the weight loss was driven mainly by fat reduction.

The drug’s effect on liver-fat reduction and preservation of lean mass are central to whether it will be able to stand out commercially, alongside tolerability and how long patients stay on the drug. Detailed data from the study could help Boehringer make a ‌stronger case ⁠that survodutide should be judged not only by pounds lost but by where weight is lost.

“We believe survodutide will become an important new option at the intersection of obesity and liver disease, two conditions that are deeply connected but rarely addressed together,” said Boehringer executive Shashank Deshpande, who leads the company’s human medicines business.

Boehringer acquired the rights in 2011 to solely develop and commercialise survodutide from Zealand, which is ⁠entitled to royalty payments on global revenue.

PATIENTS WITH LIVER DISEASE BENEFIT

In a separate late-stage study of overweight or obese patients with a fatty liver disease called MASLD, survodutide met both its main goals.

After 48 weeks, up to 84.2% of patients on the drug showed ⁠a liver fat reduction of at least 30%, compared with 24.3% for those on placebo. Patients on survodutide also lost up to 12.2% of their body weight, versus 1% for placebo.

In 61% of the patients the drug helped achieve liver fat ⁠normalization, or a liver fat content below 5%, compared with 5.7% on placebo.

U.S. biotech Altimmune (ALT.O), opens new tab is also developing a drug that targets both the appetite-suppressing gut hormone, GLP-1, and glucagon.

Survodutide is also being tested in other late-stage studies, including for patients with fatty liver disease and fibrosis.

REUTERS

Health

Millions with breast cancer could safely skip chemotherapy

Millions of people with breast cancer could safely avoid chemotherapy as scientists have developed a DNA test that can distinguish between patients who are likely to benefit from the treatment and those who are not, according to trial results.

The international study found that more than two-thirds of its participants could be spared the side of effects of chemotherapy and treated with hormone therapy alone.

Chemotherapy can cause fatigue, nausea, hair loss, a weakened immune system and fertility issues.

The study, led by University College London (UCL), involved more than 4,000 newly diagnosed patients over the age of 40 in the UK, Norway, Sweden, Australia, New Zealand and Thailand.

Scientists used a gene test called Prosigna to measure the activity of 50 genes involved in breast cancer growth and calculate a patient’s risk of the disease returning.

Those who received a low score – two-thirds of the group – were not treated through chemotherapy. The five-year survival rate of their group was 93.7%, compared with a 94.9% rate among patients who received chemotherapy as part of their care.

The primary treatment for breast cancer is usually surgery to remove tumours. Chemotherapy is often recommended afterwards to diminish the risk of return.

It is also regularly offered to people with early-stage breast cancer that has spread to the nearby lymph nodes.

Clinicians are concerned the treatment provides little benefit to those with the most common type of breast cancer, UCL said.

The university said more than 5,000 NHS patients a year could avoid chemotherapy as a result of the trial.

Karen Bonham, from Cardiff, took part in the trial and said the results are an “immense relief” and feel “like Christmas”.

The 64-year-old avoided chemotherapy thanks to the Prosigna test and has instead received radiotherapy and hormone therapy over eight years.

“Cancer diagnosis and treatment can be shocking,” she said.

“It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive.”

The findings of the study will be presented at the world’s largest cancer conference, the American Society of Clinical Oncology’s annual meeting, in Chicago, United States, on Saturday.

Professor David Miles, a leading cancer specialist, described the findings as “practice-changing”.

“We can now confidently predict many patients will get no benefit at all, and therefore there’s no need for them to have the chemotherapy,” he told BBC’s Newshour.

He added that the test would allow doctors to “confidently define a large population of women who simply aren’t going to benefit and don’t need to go through all that unpleasantness for no benefit at all.”

“We used to give chemotherapy to 100 women to benefit 10, knowing that 90 didn’t need it,” he said.

Tanya Hutson, who was diagnosed with breast cancer in 2022 and had chemotherapy as part of her treatment, called the new DNA test “absolutely amazing”.

“It just proves what happens when money is put into research,” she said, adding that chemotherapy had been “brutal”.

“For all these people out there who don’t need it but are still getting it – it’s an absolute game changer.”

It is not known whether the findings apply to people under the age of 40, with a result still several years away, according to UCL.

BBC